And, in parallel, we have immunotherapy (IT), more specifically immune checkpoint inhibitors (anti-PD-1 and anti-CTL-4), represented by pembrolizumab, nivolumab, and the combination of nivolumab and ipilimumab (NIV/IPI), which have shown consistent benefits in patients with advanced melanoma, both in BRAF-mutated and wild-type populations (5, 6). The gene discussed is BRAF; the disease is melanoma.